不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血红蛋白、白蛋白、淋巴细胞和血小板（HALP）评分在低危和早期结外自然杀伤/T 细胞淋巴瘤中的预后价值
英文原题：The prognostic value of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in low-risk and early-stage extranodal natural killer/T cell lymphoma.
查看英文原题
The prognostic value of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in low-risk and early-stage extranodal natural killer/T cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
低 HALP 评分与低危和早期 ENKTL 患者的不良临床病理特征相关，提示其可能作为独立的负向预后指标。
研究思路结论见上方概要
背景
结外自然杀伤/T细胞淋巴瘤（ENKTL）是一种侵袭性疾病，预后严峻。血红蛋白、白蛋白、淋巴细胞和血小板（HALP）评分已被确定为多种恶性肿瘤预后的预测标志物。然而，HALP评分在ENKTL背景下的预后意义尚未确立。
目的
我们的目的是评估初始HALP评分对ENKTL患者预后的预测能力。
方法
我们开展了一项回顾性分析，纳入296例新诊断并接受以培门冬酶为基础治疗的早期、低危ENKTL患者。我们评估了HALP评分作为治疗反应、总生存期（OS）和无进展生存期（PFS）预测指标的意义。
结果
所有患者的中位随访时间为72个月。我们发现低HALP评分与较差的美国东部肿瘤协作组 (ECOG)体能状态(PS)、B症状的存在、男性性别和乳酸脱氢酶(LDH)水平升高相关(均p < 0.05)，以及对治疗反应不佳(p = 0.006)。在NK 细胞淋巴瘤预后指数(PINK)模型中，HALP评分低于32.6的低危ENKTL患者5年OS显著更差，为51.8%，而HALP评分32.6或以上的患者为75.5%(p < 0.001)，5年PFS为47.1%对比69.9%(p < 0.001)。将Epstein-Barr病毒(EBV)-DNA滴度整合到PINK模型中，促成了另一个预后指数PINK-E模型的开发。根据该模型，HALP评分低于32.6的低危ENKTL患者5年OS显著更差，为46.0%，而HALP评分32.6或以上的患者为73.1%(p < 0.001)，5年PFS为40.8%对比68.5%(p < 0.001)。
展开英文摘要原文
BACKGROUND
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive disease with grim prognosis. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been identified as a predictive marker for prognosis in various malignancies. However, the prognostic significance of the HALP score in the context of ENKTL has yet to be established. AIMS: Our objective was to assess the predictive power of the initial HALP score for ENKTL patients regarding their prognosis.
METHODS
We conducted a retrospective analysis of 296 early-stage, low-risk ENKTL patients who were newly diagnosed and treated with asparaginase-based therapies. We evaluated the significance of HALP score as a predictor of response to treatment, overall survival (OS), and progression-free survival (PFS).
RESULTS
The median follow‑up for all patients was 72 months. We identified that a low HALP score was associated with a poorer Eastern Cooperative Oncology Group (ECOG) performance status (PS), the presence of B symptoms, male gender, and increased lactate dehydrogenase (LDH) levels (all p < 0.05), as well as a suboptimal response to therapy (p = 0.006). In the prognostic index of natural killer cell lymphoma (PINK) model, low-risk ENKTL patients with a HALP score below 32.6 exhibited significantly worse 5-year OS at 51.8% compared to 75.5% for those with a HALP score of 32.6 or above (p < 0.001), and 5-year PFS at 47.1% compared to 69.9% (p < 0.001). Integrating Epstein-Barr virus (EBV)-DNA titer into the PINK model led to the development of an additional prognostic index, the PINK-E model. According to this model, low-risk ENKTL patients with a HALP score below 32.6 had significantly poorer 5-year OS at 46.0% compared to 73.1% for those with a HALP score of 32.6 or above (p < 0.001), and 5-year PFS at 40.8% compared to 68.5% (p < 0.001).
CONCLUSION
Low HALP score was associated with unfavorable clinicopathological characteristics of ENKTL patients with low-risk and early-stage disease, suggesting that it may serve as an independent, negative prognostic indicator.
论文信息
- 作者
- Li N、Huang J、Xie Y、Feng Y、Min S、Zou LQ
- 第一作者单位
- Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.China
- 通讯作者单位
- Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, China. zouliqun1971@163.com.China
- 文献类型
- 评价性研究
- 期刊
- Annals of hematology2025 Aug
- 原文标识
- PubMed 40748465 · DOI 10.1007/s00277-025-06272-7
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →